Kate Hammeke, Vice President, Market Research, Industry Standard Research, told us drug product outsourcers are consistent in their prioritization of CMO selection attributes.
“The same three attributes topped the list in 2017 as 2016,” she explained. The first of these attributes being a “strong regulatory track record.”
Other CMO performance attributes evaluated by respondents included on-time delivery, quality performance metrics, scale-up and tech transfer abilities, scientific knowledge, right-first-time measurements, among others.
“With respect to top rated drug product CMOs, according to current and recent customers and based on ISR’s 27 performance metrics, there is a new set of leaders in the field this year,” said Hammeke, adding that none of last year’s leaders rose to the top for the second year in a row.
However, nearly half of the 70 companies included in the study were unheard of among almost half of the research participants — “their key buying audience, the people responsible for outsourcing drug product manufacturing,” Hammeke explained.
As such, she said more needs to be done to in increase awareness of drug product CMOs’ offerings to sponsor organizations.
The report presents data on 673 service encounters from 302 respondents who have been involved in outsourced drug product projects in the past 18 months.